Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small cell lung cancer Meeting Abstract
| Authors: | Horn, L.; Rizvi, N. A.; Mazières, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Léna, H.; Minenza, E.; Mennecier, B.; Otterson, G. A.; Campos, L. T.; Gandara, D. R.; Levy, B. P.; Nair, S. G.; Zalcman, G.; Wolf, J.; Paik, P.; Li, A.; Xu, D.; Neely, J.; Qi, Z.; Harbison, C.; Lynch, M.; Ramalingam, S. S. |
| Abstract Title: | Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small cell lung cancer |
| Meeting Title: | 16th World Conference on Lung Cancer (WCLC) |
| Keywords: | immunotherapy; pd-l1; nivolumab; squamous cell nsclc |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 10 |
| Issue: | 9 Suppl. 2 |
| Meeting Dates: | 2015 Sep 6-9 |
| Meeting Location: | Denver, CO |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S175 |
| End Page: | S176 |
| Language: | English |
| ACCESSION: | WOS:000370365100216 |
| PROVIDER: | wos |
| PUBMED: | 26710300 |
| DOI: | 10.1016/S1556-0864(16)30010-7 |
| Notes: | Meeting Abstract: ORAL02.03 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
